Share this article
Share this article
HORSHAM, Pa., May 21, 2021 /PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has granted the accelerated approval of RYBREVANT
TM (amivantamab-vmjw) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
1 RYBREVANT
TM is the first fully-human, bispecific antibody approved for the treatment of patients with NSCLC that targets EGFR exon 20 insertion mutations, which are the third most prevalent activating EGFR mutation.
Janssen Receives Two Positive CHMP Opinions Recommending Expanded Use of DARZALEX? (daratumumab) Subcutaneous (SC) Formulation for New Indications in Europe
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
EQS-News: PJSC Mechel: Mechel Reports 1Q2021 Operational Results
PJSC Mechel: Mechel Reports 1Q2021 Operational Results
20.05.2021 / 13:00 MSK
MECHEL REPORTS 1Q2021 OPERATIONAL RESULTS
Moscow, Russia - May 20, 2021 - Mechel PAO (MOEX: MTLR, NYSE: MTL), one of the leading Russian mining and metals companies, announces 1Q2021 operational results.
Mechel PAO s Chief Executive Officer Oleg Korzhov commented on operational results. Our operational dynamics in 1Q2021 were largely what they were due to conditions our company worked in last year, caused by both external and internal factors. Even as the decrease in debt leverage due to restructuring and partial repayment of our loans had its positive impact, starting in April-May Mechel felt the lack of cash flow sufficient for financing our operations as needed. This was due to a major slump in coal and steel prices because of the pandemic. Underfunding of our operations in the second half of last year led to a major reduction in s
EQS-News: PJSC Mechel : Mechel Reports the 1Q 2021 Financial Results
vom 20.05.2021, 11:30 Uhr
Bild: pixabay.com
PJSC Mechel : Mechel Reports the 1Q 2021 Financial Results
20.05.2021 / 12:30 MSK
MECHEL REPORTS THE 1Q 2021 FINANCIAL RESULTS
EBITDA[ ] - 18.2 bln rubles (+39% compared to 1Q 2020)
Profit attributable to equity shareholders of Mechel PAO - 7.9 bln rubles
Moscow, Russia - May 20, 2021 - Mechel PAO (MOEX: MTLR, NYSE: MTL), a leading Russian mining and steel group, announces financial results for the 1Q 2021.
Mechel PAO s Chief Executive Officer Oleg Korzhov commented: The Group s consolidated revenue in 1Q2021 was 76.0 billion rubles, which is 10% more than in the previous quarter. EBITDA reached 18.2 billion rubles, demonstrating an 88% growth quarter-on-quarter.
PJSC Mechel : Mechel Reports 1Q2021 Operational Results
EquityStory.RS, LLC-News: PJSC Mechel / Key word(s): Quarter Results
20.05.2021 / 13:00 MSK
MECHEL REPORTS 1Q2021 OPERATIONAL RESULTS
Moscow, Russia - May 20, 2021 - Mechel PAO (MOEX: MTLR, NYSE: MTL), one of the leading Russian mining and metals companies, announces 1Q2021 operational results.
Mechel PAO s Chief Executive Officer Oleg Korzhov commented on operational results. Our operational dynamics in 1Q2021 were largely what they were due to conditions our company worked in last year, caused by both external and internal factors. Even as the decrease in debt leverage due to restructuring and partial repayment of our loans had its positive impact, starting in April-May Mechel felt the lack of cash flow sufficient for financing our operations as needed. This was due to a major slump in coal and steel prices because of the pandemic. Underfunding of our operations in the second half of last year led to a major re
vimarsana © 2020. All Rights Reserved.